CMS Pay For Off-Label Use Of Avastin In Wet Age-Related Macular Degeneration May Discourage Use

Rate based on Avastin's cancer indication puts ophthalmologists in the position of choosing whether to take a loss to administer it to Medicare beneficiaries or get full reimbursement for the more expensive, FDA-approved Lucentis.